RPID · Rapid Micro Biosystems, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $8.00M | - | $7.84M | $7.26M | $7.21M | - | $7.60M | $6.62M | $5.61M | - |
| Cost of Revenue | $7.63M | - | - | - | - | - | - | - | - | - |
| Gross Profit | $404.0K | - | - | - | - | - | - | - | - | - |
| R&D | $3.36M | - | $3.53M | $3.23M | $3.62M | - | $3.61M | $3.74M | $3.84M | - |
| SG&A | $7.44M | - | $5.64M | $6.08M | $5.69M | - | $5.68M | $5.82M | $5.63M | - |
| Total Operating Expenses | $12.06M | - | $19.21M | $19.41M | $18.87M | - | $19.64M | $20.00M | $19.88M | - |
| D&A | $706.0K | - | - | - | $847.0K | - | - | - | $806.0K | - |
| Operating Income | ($13.85M) | - | ($11.37M) | ($12.15M) | ($11.66M) | - | ($12.04M) | ($13.38M) | ($14.27M) | - |
| Interest Expense | $12.0K | - | $11.0K | - | - | - | - | - | - | - |
| Income Tax | $8.0K | - | $8.0K | $11.0K | $7.0K | - | $13.0K | $15.0K | $3.0K | - |
| Net Income | ($14.28M) | - | ($11.51M) | ($11.86M) | ($11.26M) | - | ($11.32M) | ($12.58M) | ($13.32M) | - |
| EPS - Basic | ($0.31) | - | ($0.26) | ($0.27) | ($0.26) | - | ($0.26) | ($0.29) | ($0.31) | - |
| EPS - Diluted | ($0.31) | - | ($0.26) | ($0.27) | ($0.26) | - | ($0.26) | ($0.29) | ($0.31) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $13.81M | $20.03M | $18.95M | $18.33M | $18.91M | $16.91M | $22.04M | $37.12M | $22.43M | $24.29M |
| Accounts Receivable | $6.37M | $3.13M | $5.43M | $6.05M | $4.52M | $7.52M | $3.74M | $5.01M | $4.92M | $5.53M |
| Inventory | $17.45M | $17.59M | $21.07M | $20.56M | $20.72M | $20.20M | $21.25M | $21.43M | $20.42M | $19.96M |
| Accounts Payable | $4.67M | $4.14M | $3.59M | $3.33M | $2.63M | $2.54M | $2.33M | $2.18M | $1.16M | $1.97M |
| Current Assets | $49.23M | $61.17M | $69.95M | $60.15M | $69.18M | $80.92M | $87.93M | $98.20M | $108.16M | $120.42M |
| Total Assets | $62.36M | $74.85M | $84.41M | $75.59M | $85.43M | $98.17M | $105.84M | $117.08M | $127.73M | $143.45M |
| Current Liabilities | $19.12M | $18.49M | $16.55M | $16.40M | $15.00M | $17.57M | $15.92M | $16.60M | $15.60M | $18.99M |
| Long-term Debt | $19.05M | $18.90M | $0 | - | - | - | - | - | - | - |
| Total Liabilities | $41.97M | $41.65M | $40.08M | $21.04M | $19.94M | $22.82M | $21.47M | $22.50M | $21.79M | $25.46M |
| Stockholders' Equity | $20.40M | $33.21M | $44.33M | $54.55M | $65.49M | $75.35M | $84.37M | $94.59M | $105.94M | $117.99M |
| Retained Earnings | ($536.67M) | ($522.40M) | ($509.90M) | ($498.39M) | ($486.54M) | ($475.27M) | ($465.61M) | ($454.29M) | ($441.71M) | ($428.38M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($15.06M) | - | - | - | ($9.06M) | - | - | - | ($15.53M) | - |
| Investing Cash Flow | $8.60M | - | - | - | $10.68M | - | - | - | $13.52M | - |
| Financing Cash Flow | $247.0K | - | - | - | $379.0K | - | - | - | $158.0K | - |
| CapEx | $394.0K | - | - | - | $319.0K | - | - | - | $585.0K | - |
| Free Cash Flow | ($15.45M) | - | - | - | ($9.38M) | - | - | - | ($16.11M) | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | 5.0% | - | - | - | - | - | - | - | - | - |
| Operating margin | -173.1% | - | -145.1% | -167.3% | -161.8% | - | -158.3% | -202.1% | -254.4% | - |
| EBITDA margin | -164.3% | - | - | - | -150.1% | - | - | - | -240.0% | - |
| Net margin | -178.4% | - | -146.8% | -163.3% | -156.3% | - | -148.9% | -190.1% | -237.4% | - |
| Free cash flow margin | -193.1% | - | - | - | -130.2% | - | - | - | -287.1% | - |
| FCF / Net income | 1.08 | - | - | - | 0.83 | - | - | - | 1.21 | - |
| R&D / Revenue | 42.0% | - | 45.0% | 44.5% | 50.3% | - | 47.5% | 56.6% | 68.5% | - |
| SG&A / Revenue | 93.0% | - | 72.0% | 83.7% | 79.0% | - | 74.6% | 87.9% | 100.3% | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -22.9% | - | -13.6% | -15.7% | -13.2% | - | -10.7% | -10.7% | -10.4% | - |
| Return on equity | -70.0% | - | -26.0% | -21.7% | -17.2% | - | -13.4% | -13.3% | -12.6% | - |
| Return on invested capital | -27.7% | - | -20.3% | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 2.57 | 3.31 | 4.23 | 3.67 | 4.61 | 4.61 | 5.52 | 5.92 | 6.93 | 6.34 |
| Quick ratio | 1.66 | 2.36 | 2.95 | 2.41 | 3.23 | 3.46 | 4.19 | 4.62 | 5.62 | 5.29 |
| Cash ratio | 0.72 | 1.08 | 1.14 | 1.12 | 1.26 | 0.96 | 1.38 | 2.24 | 1.44 | 1.28 |
| Leverage | ||||||||||
| Debt / Equity | 0.93 | 0.57 | 0.00 | - | - | - | - | - | - | - |
| Debt / Assets | 0.31 | 0.25 | 0.00 | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | -1154.3x | - | -1033.8x | - | - | - | - | - | - | - |
| Equity multiplier | 3.06 | 2.25 | 1.90 | 1.39 | 1.30 | 1.30 | 1.25 | 1.24 | 1.21 | 1.22 |
| Liabilities / Assets | 0.67 | 0.56 | 0.47 | 0.28 | 0.23 | 0.23 | 0.20 | 0.19 | 0.17 | 0.18 |
| Efficiency | ||||||||||
| Asset turnover | 0.13 | - | 0.09 | 0.10 | 0.08 | - | 0.07 | 0.06 | 0.04 | - |
| Inventory turnover | 0.44 | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | 290d | - | 253d | 304d | 229d | - | 180d | 276d | 320d | - |
| Days inventory outstanding | 835d | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | 223d | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | 902d | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | 5.1x | - | 3.4x | 2.8x | 1.8x | - | 0.5x | 0.3x | 0.4x | - |
| P / S | 12.9x | - | 19.2x | 21.2x | 16.1x | - | 5.1x | 4.3x | 7.5x | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | 11.1% | - | 3.1% | 9.7% | 28.4% | - | 23.7% | 32.3% | 11.4% | - |
| Revenue CAGR (3y) | 16.7% | - | 18.3% | 23.4% | 13.0% | - | 13.2% | 36.7% | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | -18.8% | - | 5.5% | 9.2% | 18.3% | - | 16.7% | 11.1% | 4.0% | - |
| Net income growth (YoY) | -26.7% | - | -1.6% | 5.7% | 15.5% | - | 15.4% | 10.3% | 4.1% | - |
| EPS growth (YoY) | -19.2% | - | 0.0% | 6.9% | 16.1% | - | 16.1% | 12.1% | 3.1% | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | -64.7% | - | - | - | 41.8% | - | - | - | 7.7% | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -68.9% | -55.9% | -47.5% | -42.3% | -38.2% | -36.1% | -34.0% | -32.3% | -30.5% | -28.1% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Product / service
$51.43M totalProduct$23.43M · 45.6%
Product And Service$17.84M · 34.7%
Service$10.16M · 19.8%
Geographic
$33.59M totalUS$13.43M · 40.0%
CH$6.02M · 17.9%
All Other Countries$5.77M · 17.2%
DE$5.77M · 17.2%
JP$2.60M · 7.7%
Peer comparison
Same SIC group: Laboratory Analytical Instruments
Comparing RAPID MICRO BIOSYSTEMS against the 5 most active filers in the same SIC group.